Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2004

View Archived Issues

Efficacy of ezetimibe shown in hypercholesterolemic kidney transplant patients

Official webcasts from the American Urological Association's 99th Annual Meeting

Novel potent tryptase inhibitor described by BMS

Novel factor Xa inhibitor with potent anticoagulant and antithrombotic activity

Argenta Discovery seeks to out-license HDAC inhibitor project

Protein Design Labs discontinues development of daclizumab for ulcerative colitis

BMS, Gilead and Merck to develop fixed-dose combination of three anti-HIV drugs

BMS and Solvay to codevelop SLV-319

SkyePharma enters agreement for undisclosed cardiovascular pipeline product

Chiron Vaccines' powder injection vaccine technology development to continue under PowderMed

Benitec gains ddRNAi-based therapeutic for HCV through Avocel acquisition

NIH initiates 5-year study of severe, treatment-resistant systemic lupus

Phase IIa study of AD-237 in treatment of COPD shows positive results

Guilford expands international network for Gliadel Wafer through second agreement

Lasofoxifene counters bone loss in postmenopausal women

Strontium ranelate reduces hip fracture risk in older postmenopausal women

Intravenous ferumoxytol effective in anemic patients on hemodialysis

Lanthanum carbonate findings reported at NKF meeting

In vitro and clinical data on dalbavancin reported at ECCMID

Bay-73-7388 demonstrates efficacy in vitro and in vivo

Talnetant stimulates peristalsis without affecting normal intestinal motility

Benefits of the antioxidant tetrathiomolybdate in experimental colitis

TC-240312 reported to inhibit the production of IL-8 in the intestinal mucosa

Merck claims radiolabeled NK1 antagonists and their use as diagnostic agents

Portela describes peripherally acting dopamine beta-hydroxylase inhibitors

Janssen presents p38/TNF-alpha inhibitors and their use in inflammatory disorders

Two series of HIV RT inhibitors in early development at Pfizer

Novel Abl kinase inhibitors identified by Novartis researchers

Novel 11a-azaerythromycin analogues and their use reported by Pliva

New 5-HT6 antagonists prepared and tested by Roche team